Literature DB >> 20184513

Dysarthria in amyotrophic lateral sclerosis: A review.

Barbara Tomik1, Roberto J Guiloff.   

Abstract

Dysarthria is a motor disorder of speech characterized by abnormalities of the articulation and intelligibility of speech. Phonation and the rate of facial movements may also be affected. Understanding the nature and course of dysarthria in amyotrophic lateral sclerosis (ALS) is important because loss of communication prevents patients from participating in many activities, may lead to social isolation, and reduces the quality of life. The goal of management of dysarthria in ALS patients is to optimize communication effectiveness for as long as possible. The information about dysarthria in ALS is dispersed in physiological, pathological, speech therapy, otorhinolaringological and neurological publications. This review summarizes the current state of knowledge on the clinical features, differential diagnosis, pathophysiology, investigations and management of dysarthria in ALS patients. There is a need to compare the different methods used to assess dysarthria and for controlled clinical trials to assess therapeutic strategies.

Entities:  

Mesh:

Year:  2010        PMID: 20184513     DOI: 10.3109/17482960802379004

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler        ISSN: 1471-180X


  28 in total

1.  Electrical impedance myography in the evaluation of the tongue musculature in amyotrophic lateral sclerosis.

Authors:  Sanjana Shellikeri; Yana Yunusova; Jordan R Green; Gary L Pattee; James D Berry; Seward B Rutkove; Lorne Zinman
Journal:  Muscle Nerve       Date:  2015-06-03       Impact factor: 3.217

2.  Black hairy tongue in a patient with amyotrophic lateral sclerosis.

Authors:  Matteo Erriu; Francesca Maria Giovanna Pili; Gloria Denotti; Valentino Garau
Journal:  J Int Soc Prev Community Dent       Date:  2016 Jan-Feb

3.  Clinical and imaging characterization of progressive spastic dysarthria.

Authors:  H M Clark; J R Duffy; J L Whitwell; J E Ahlskog; E J Sorenson; K A Josephs
Journal:  Eur J Neurol       Date:  2013-09-19       Impact factor: 6.089

4.  Adult normative values for the PATA Rate Test.

Authors:  Chiara Pane; Teresa Costabile; Adriana Salvati; Dalila Luisa Aurisicchio; Filomena Abate; Angese Liguori; Francesca Paciello; Silvio Peluso; Fiore Manganelli; Giuseppe De Michele; Alessandro Filla; Francesco Saccà
Journal:  J Neurol       Date:  2018-03-06       Impact factor: 4.849

5.  Kinematic Features of Jaw and Lips Distinguish Symptomatic From Presymptomatic Stages of Bulbar Decline in Amyotrophic Lateral Sclerosis.

Authors:  Andrea Bandini; Jordan R Green; Jun Wang; Thomas F Campbell; Lorne Zinman; Yana Yunusova
Journal:  J Speech Lang Hear Res       Date:  2018-05-17       Impact factor: 2.297

6.  Detecting Bulbar Motor Involvement in ALS: Comparing speech and chewing tasks.

Authors:  Erin M Wilson; Madhura Kulkarni; Meg Simione; Panying Rong; Jordan R Green; Yana Yunusova
Journal:  Int J Speech Lang Pathol       Date:  2019-01-29       Impact factor: 2.484

7.  Shorter Sentence Length Maximizes Intelligibility and Speech Motor Performance in Persons With Dysarthria Due to Amyotrophic Lateral Sclerosis.

Authors:  Kristen M Allison; Yana Yunusova; Jordan R Green
Journal:  Am J Speech Lang Pathol       Date:  2019-02-21       Impact factor: 2.408

8.  Hypoglossal Motor Neuron Death Via Intralingual CTB-saporin (CTB-SAP) Injections Mimic Aspects of Amyotrophic Lateral Sclerosis (ALS) Related to Dysphagia.

Authors:  Lori A Lind; Erika R Murphy; Teresa E Lever; Nicole L Nichols
Journal:  Neuroscience       Date:  2018-09-01       Impact factor: 3.590

Review 9.  Rehabilitation in amyotrophic lateral sclerosis: why it matters.

Authors:  Salony Majmudar; Jason Wu; Sabrina Paganoni
Journal:  Muscle Nerve       Date:  2014-05-17       Impact factor: 3.217

10.  Development of a model to guide decision making in amyotrophic lateral sclerosis multidisciplinary care.

Authors:  Anne Hogden; David Greenfield; Peter Nugus; Matthew C Kiernan
Journal:  Health Expect       Date:  2013-12-23       Impact factor: 3.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.